ulodesine (LR 09) / Laevoroc Oncology, UCLA, Fred Hutchinson Cancer Center - LARVOL DELTA

Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant (GlobeNewswire) - "Laevoroc Immunology...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for LR 09, a novel metabolic immune checkpoint inhibitor, for the treatment of patients with haematological malignancies who are diagnosed with a relapse after allogeneic stem cell transplant (SCT)."

Orphan drug • Hematological Malignancies • Oncology

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia (PRNewswire) - "Agreements with UCLA and Fred Hutchinson Cancer Research Center to support LR09 drug development....Laevoroc Oncology...announced today the appointment of Shanta Bantia, PhD, as CSO of Laevoroc Immunology, an asset-centric subsidiary of Laevoroc, developing a highly potent Purine Nucleoside Phosphorylase (PNP) inhibitor, LR 09 (Ulodesine), to guide the immune system to eradicate relapsed leukemia after stem cell transplantation."

Licensing / partnership • Graft versus Host Disease • Hematological Malignancies • Leukemia • Oncology